Prescription drug rehab at Villa Treatment Center serves Los Angeles with medical detox, residential, partial hospitalization, intensive outpatient, and outpatient care for prescription opioid, benzodiazepine, stimulant, and sleep medication addiction. Multi-class clinical care matched to the specific medication. Most major insurance accepted. Admissions answer 24/7.
If you or someone you love is in crisis right now, including overdose risk or thoughts of self-harm, call 911 or 988 (Suicide and Crisis Lifeline). Severe benzodiazepine withdrawal can cause seizures and is life-threatening if discontinued abruptly. Suspected opioid overdose requires 911 plus Naloxone if available. Villa’s admissions team can help you decide on next steps; call (818) 639-7160 any time.
Prescription Drug Classes We Treat
Prescription drug addiction is not one condition. The clinical reality differs significantly by class, and treatment must be matched to the specific medication. Villa treats:
- Prescription opioids oxycodone (OxyContin, Percocet), hydrocodone (Vicodin, Norco), fentanyl (transdermal patches, lozenges, illicit-source fentanyl), morphine, codeine, tramadol, methadone misuse
- Benzodiazepines alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), temazepam (Restoril)
- Prescription stimulants amphetamines (Adderall, Vyvanse, Dexedrine), methylphenidate (Ritalin, Concerta), modafinil (Provigil)
- Z-drugs and sleep medications zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata)
- Other prescription medications with abuse potential muscle relaxants (Soma), gabapentin and pregabalin (Lyrica), promethazine (Phenergan with codeine), and others
- Polysubstance prescription patterns prescription opioid plus benzodiazepine (high-overdose-risk combination), prescription stimulants plus alcohol or cocaine; the most clinically complex presentations
Many clients with prescription drug addiction began with legitimate medical use (post-surgical pain, anxiety, ADHD, insomnia) and developed dependence over time. This pattern is common, is not a personal failure, and shapes the treatment approach.
Prescription opioid addiction
Prescription opioid use disorder is clinically the same condition as heroin use disorder both involve the brain’s opioid receptors and respond to the same evidence-based treatments. The starting point is often different (legitimate prescription for pain), but the trajectory and treatment framework are the same.
Withdrawal. Opioid withdrawal is rarely medically dangerous but is intensely uncomfortable: severe muscle aches, GI symptoms, sweating, anxiety, intense cravings. Acute phase peaks days 1-3 and subacute symptoms continue 5-10 days. Post-acute craving and mood symptoms can persist for months.
Medication-Assisted Treatment (MAT). MAT is the strongest evidence-based intervention for opioid use disorder including prescription opioids:
- Buprenorphine (Suboxone, Subutex) first-line; reduces craving and prevents withdrawal without producing the high; long-term use is supported by research and produces the lowest relapse and overdose-mortality rates
- Naltrexone (Vivitrol) monthly injection that blocks opioid effect; useful for clients who prefer non-agonist MAT; must be started after detox is fully complete
- Methadone long-acting full agonist available through licensed Opioid Treatment Programs (OTPs); Villa coordinates referrals
For full opioid clinical content including fentanyl considerations, see heroin rehab in Los Angeles, which addresses the same opioid use disorder framework.
Benzodiazepine Addiction a Special Clinical Case
Benzodiazepine addiction requires distinct clinical handling because abrupt discontinuation can cause seizures and is medically dangerous. This is fundamentally different from opioid or stimulant withdrawal, where withdrawal is uncomfortable but rarely life-threatening.
Why benzodiazepines are different. Benzodiazepines suppress central nervous system activity; abrupt discontinuation creates rebound hyperexcitability that can produce seizures, particularly after long-term use or high-dose use. The longer and higher-dose the use, the more dangerous abrupt discontinuation becomes. Clients have died from unsupervised benzodiazepine withdrawal.
Standard treatment approach. Structured taper over weeks to months, depending on duration and dose. The taper typically uses a long-acting benzodiazepine (often diazepam or chlordiazepoxide), which has a smoother withdrawal profile than short-acting benzodiazepines like Xanax. Anti-seizure medications may be added when clinically indicated.
Timeline. Benzodiazepine detox is typically 2-4 weeks of structured taper; in some cases, taper continues for months in an outpatient setting. This is significantly longer than opioid or stimulant detox.
Post-acute withdrawal. Even after physical detox is complete, benzodiazepine post-acute withdrawal syndrome (PAWS) can include anxiety, sleep difficulty, and cognitive symptoms lasting weeks to months. This is treatable but requires patience and clinical support.
Co-occurring anxiety. Most clients with benzodiazepine addiction have underlying anxiety that drove the original prescription. Treatment for the underlying anxiety anxiety treatment is essential to prevent relapse.
Prescription stimulant addiction
Prescription stimulants (Adderall, Vyvanse, Ritalin, Concerta) are increasingly misused, particularly among college students, young professionals, and clients self-medicating undiagnosed ADHD.
Withdrawal. Like cocaine and methamphetamine, stimulant withdrawal is rarely medically dangerous but produces severe psychological symptoms: deep fatigue, depression, increased appetite, anhedonia, intense cravings. Sleep disruption is common during the acute phase.
Common pattern: ADHD self-medication. Some clients with prescription stimulant misuse have undiagnosed adult ADHD. The stimulant initially worked because they actually had ADHD; the addiction developed because the dose escalated beyond therapeutic. Treatment in this case includes proper ADHD diagnosis and a careful decision about non-stimulant or carefully-monitored stimulant medication going forward; see adult ADHD treatment.
Treatment approach. Like other stimulants, treatment is fundamentally behavioral there is no FDA-approved medication specifically for stimulant use disorder. CBT, contingency management, the Matrix Model, and management of co-occurring conditions are the evidence-based components. See cocaine rehab in Los Angeles and meth rehab in Los Angeles for related stimulant clinical frameworks.
Z-drugs and Sleep Medication Addiction
Zolpidem (Ambien), eszopiclone (Lunesta), and zaleplon (Sonata) are commonly misused for euphoric effect, recreational use, or to escape insomnia that has become tolerance-driven by the medication itself.
Withdrawal. Z-drug withdrawal can resemble benzodiazepine withdrawal in some cases, with rebound insomnia, anxiety, and in long-term high-dose use, seizure risk. Treatment approach is similar to benzodiazepines: structured taper, anti-seizure medication when indicated, treatment for underlying insomnia.
Underlying insomnia treatment. Most clients with sleep medication addiction have underlying chronic insomnia. Cognitive Behavioral Therapy for Insomnia (CBT-I) is the evidence-based first-line treatment for chronic insomnia and produces sustained improvement without medication dependence. Villa integrates CBT-I as part of the treatment plan when clinically indicated.
How prescription drug addiction is treated at Villa
The treatment continuum is matched to the drug class and the individual’s circumstances:
Medical detox essential for benzodiazepines (medical risk during withdrawal) and Z-drugs at high dose; often clinically appropriate for opioids (comfort, MAT induction); generally not medically required for stimulants but often clinically appropriate.
Residential treatment for clients needing 24/7 structure during the high-relapse-risk first phase. Typically 30 to 90 days; the 90-day length has the strongest research outcomes for substance use disorders. Particularly important for benzodiazepine clients given the longer detox timeline.
Partial hospitalization (PHP) at 5-6 hours/day, 5 days/week.
Intensive outpatient (IOP) at 3 hours/day, 3 days/week.
Outpatient therapy and medication management for sustained maintenance. Opioid use disorder clients on MAT often continue indefinitely, long-term MAT is standard, evidence-based, and produces the lowest relapse rates.
The first appointment is a 90-minute clinical assessment covering full mental health history, prescription medication history including original prescribing context, current dose, withdrawal stage, medical complications, screening for co-occurring conditions, and treatment plan recommendations.
Therapeutic modalities
Villa’s clinicians practice evidence-based modalities matched to the client’s diagnosis:
- Cognitive Behavioral Therapy (CBT) first-line for substance use across all classes
- Motivational Interviewing (MI) for ambivalence about change in early treatment
- Trauma-focused therapy (EMDR, prolonged exposure, CPT) trauma frequently underlies prescription drug use, particularly when use began with legitimate medical treatment for pain or anxiety
- DBT skills emotion regulation, distress tolerance, mindfulness
- CBT-I (Cognitive Behavioral Therapy for Insomnia) for clients with sleep medication addiction or insomnia underlying other prescription use
- Relapse prevention curriculum structured protocols for trigger identification and high-risk situation planning
- Contingency Management (CM) evidence-based incentives for sustained abstinence
- 12-step facilitation supports engagement with NA, Pills Anonymous, AA, and other community recovery
- SMART Recovery secular, science-based recovery community
- Group therapy see group therapy programs
- Individual therapy see individual therapy
- Family therapy see family therapy programs; prescription drug addiction frequently affects intimate relationships and family systems
- Pain management coordination for opioid clients whose addiction began with legitimate pain treatment, treatment includes coordination with addiction-medicine-aware pain management to prevent relapse without leaving real pain untreated
Clinicians are licensed Marriage and Family Therapists (LMFT) and Licensed Clinical Social Workers (LCSW). Medically reviewed by Dr. Courtney Scott, MD. Founded by Georgia Frabotta, who brings over 23 years of personal recovery experience.
Co-occurring conditions in prescription drug addiction
Prescription drug addiction frequently co-occurs with the conditions the medication was originally prescribed for, plus other mental health diagnoses:
- Prescription opioid use with chronic pain the most common pattern; requires coordination with pain management, often including non-opioid pain approaches
- Benzodiazepine use with anxiety disorders see anxiety treatment; proper anxiety treatment with non-addictive medications and CBT/exposure therapy is essential to prevent relapse
- Prescription stimulant use with adult ADHD see adult ADHD treatment; proper ADHD diagnosis and non-stimulant or carefully-monitored medication management addresses the underlying driver
- Sleep medication use with chronic insomnia CBT-I as the evidence-based first-line treatment; underlying causes (sleep apnea, depression, anxiety) addressed clinically
- Prescription drug use with depression see depression treatment; both pre-existing depression and depression that emerges during recovery
- Prescription drug use with PTSD or trauma see PTSD treatment; trauma is common in addiction histories
- Prescription drug use with bipolar disorder see bipolar disorder treatment
Villa is licensed for co-occurring disorders treatment; see dual diagnosis treatment for integrated care.
Insurance, cost, and admissions
Villa Treatment Center is in-network with Aetna, Cigna, Anthem Blue Cross, Blue Cross of California, Health Net, and MHN, and works with most other major carriers on an out-of-network basis. Prescription drug addiction treatment, MAT, and the full continuum of care are covered under the behavioral health benefit. Buprenorphine and Vivitrol are typically covered with prior authorization.
Verification takes 15 minutes by phone or 24 hours by online form. Self-pay rates and payment plans are available.To start: call (818) 639-7160 or use the insurance verification form. Detox intake particularly for benzodiazepines is scheduled urgently when clinically appropriate.
Serving Los Angeles, the San Fernando Valley, and Surrounding Areas
Villa’s facility sits on Hood Drive in Woodland Hills, CA, accessible from across Los Angeles, Hollywood, Beverly Hills, Brentwood, Bel Air, Malibu, Westwood, Santa Monica, Calabasas, Tarzana, Encino, Sherman Oaks, Northridge, West Hills, Canoga Park, Reseda, Van Nuys, Agoura Hills, Glendale, and the broader LA metro area. Telehealth extends outpatient prescription drug addiction treatment across California.
Frequently asked questions
Clinically, the underlying conditions are often the same. Prescription opioid use disorder and heroin use disorder both involve the brain’s opioid receptors and respond to the same MAT and behavioral treatments. Prescription stimulant use disorder and cocaine use disorder are clinically similar. The starting point is often different (legitimate prescription versus illicit use), but the trajectory and treatment framework converge.
Benzodiazepines suppress central nervous system activity; abrupt discontinuation creates rebound hyperexcitability that can produce seizures, particularly with long-term or high-dose use. Opioid withdrawal is intensely uncomfortable but rarely produces seizures or other life-threatening medical complications. Benzodiazepine detox always uses a structured taper over weeks; abrupt discontinuation is medically dangerous.
Length varies by drug class and severity. Opioid detox typically runs 5-10 days. Benzodiazepine detox typically runs 2-4 weeks of structured taper. Stimulant acute phase runs 5-7 days. Residential treatment runs 30-90 days; the 90-day length has the strongest research outcomes. PHP and IOP add weeks to months. Long-term outpatient continues 6-12 months or longer; opioid clients on MAT often continue indefinitely.
This depends on the specific medication and circumstances. For opioids, MAT (buprenorphine, methadone) replaces the original opioid with a clinically managed long-term treatment medication, this is not the same as continuing the original prescription. For benzodiazepines, the answer is typically no; structured taper to off the medication is standard. For stimulants used to self-medicate ADHD, careful clinical work may produce a treatment plan that includes properly-monitored stimulant medication. The clinical assessment determines the right pathway.
Most major insurance plans cover prescription drug addiction treatment under the behavioral health benefit. Detox and residential are typically well-covered when medically necessary, particularly for benzodiazepines where medical detox is the standard of care. MAT for opioids is typically covered with prior authorization. Verification takes 15 minutes; call (818) 639-7160.
Fentanyl addiction is a rapidly growing presentation, both from prescribed transdermal fentanyl that escalated and from illicit-source fentanyl. Treatment uses the opioid use disorder framework with MAT (buprenorphine or naltrexone), residential structure, and intensive overdose risk education including Naloxone training. Fentanyl’s potency means relapse carries dramatically higher overdose risk than other opioid relapse.
No. Prescription drug addiction frequently begins with legitimate medical use post-surgical pain, anxiety treatment, ADHD treatment, insomnia. This pattern is common and is not a personal failure. The treatment approach incorporates this context: addressing the original underlying condition (pain, anxiety, ADHD, insomnia) with non-addictive approaches alongside addiction treatment.
Yes. Polysubstance use is common; prescription opioid + benzodiazepine combinations, prescription stimulant + alcohol combinations, and others are frequent. Villa’s clinical team treats all substances simultaneously rather than sequentially.
No. Most insurance plans do not require a referral for substance use treatment, though some HMO plans do. Call (818) 639-7160 or use the verification form.
